{"schema_version":"1.0","type":"article","title":"灰色產業上牌桌","url":"https://drugnews.com.tw/articles/2026-04-28-dcard-261381952.html","markdown_url":"https://drugnews.com.tw/articles/2026-04-28-dcard-261381952.md","lang":"zh-Hant","date":"2026-04-28","publish_at":"2026-04-28T10:30:00+08:00","updated_at":"2026-04-28","category":"商業分析系列","topic":"商業分析系列","tags":["商業分析系列","免費文章","AI","GLP-1","臨床數據","生技投資","製藥巨頭"],"summary":"🌪️ 在一處私人莊園裡，矽谷創業者、生技極客與華爾街資金坐在同一張桌上，話題從 AI、加密貨幣一路滑向更隱密的領域：BPC-157、MOTS-c、TB-500、Semax、Epitalon。這些名字不像藥，更像暗號。","key_points":[],"facts":[],"sections":["一場灰市轉正的風暴：胜肽熱潮，正在重寫全球新藥與供應鏈版圖","📌 不是全面開放，而是把需求拉回可監管框架","⚠️ 灰市早就長大，大到無法假裝不存在","🧭 Kennedy 路線的爭議：堵也不是，放也不是","💊 產業真正要搶的，不只是需求，而是承接需求的能力","🌍 全球胜肽產業，正在分裂成兩條敘事","🏭 亞洲供應鏈的角色，其實被低估了","🚀 下一輪創新，不一定只發生在肥胖針劑","🇹🇼 台灣讀者真正該關注的是什麼？","📝 最後，真正的問題不是要不要胜肽，而是誰來定義下一輪秩序"],"references":[{"title":"[0]: 各公司官網＆公開資料","source":"","date":"","url":""},{"title":"[1]:","source":"","date":"","url":""},{"title":"reuters.com","source":"","date":"","url":""},{"title":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-convene-expert-panel-decide-broader-access-some-peptides-2026-04-15/","source":"","date":"","url":"https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-convene-expert-panel-decide-broader-access-some-peptides-2026-04-15/"},{"title":"www.reuters.com","source":"","date":"","url":""},{"title":"[2]:","source":"","date":"","url":""},{"title":"July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026","source":"FDA","date":"","url":""},{"title":"On July 23-24, 2026, the Committee will discuss bulk drug substances being considered for inclusion on the 503A Bulks List.","source":"","date":"","url":""},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"[3]:","source":"","date":"","url":""},{"title":"‘I wouldn’t dare take these drugs’: how China supplies untested peptides to the west","source":"","date":"","url":""},{"title":"The success of weight-loss drugs has driven demand for injectable compounds that claim to improve everything from sleep to skin","source":"","date":"","url":""},{"title":"www.ft.com","source":"","date":"","url":""},{"title":"[4]:","source":"","date":"","url":""},{"title":"FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss","source":"FDA","date":"","url":""},{"title":"FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss","source":"","date":"","url":""},{"title":"www.fda.gov","source":"","date":"","url":""},{"title":"[5]:","source":"","date":"","url":""},{"title":"FDA to weigh easing limits on unproven peptides favored by RFK Jr.","source":"AP News","date":"","url":""},{"title":"Federal health officials will meet this summer to consider easing restrictions on a controversial group of drugs popular with followers of Robert F. Kennedy Jr.'","source":"","date":"","url":""},{"title":"apnews.com","source":"","date":"","url":""}],"images":[{"alt":"Dcard 原圖：灰色產業上牌桌（圖 1）","url":"https://drugnews.com.tw/assets/articles/dcard-261381952/dcard-01.webp"},{"alt":"Dcard 原圖：灰色產業上牌桌（圖 2）","url":"https://drugnews.com.tw/assets/articles/dcard-261381952/dcard-02.webp"},{"alt":"Dcard 原圖：灰色產業上牌桌（圖 3）","url":"https://drugnews.com.tw/assets/articles/dcard-261381952/dcard-03.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/dcard-261381952/dcard-01.webp","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-04-28）。灰色產業上牌桌。https://drugnews.com.tw/articles/2026-04-28-dcard-261381952.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{"en":"2026-04-28-dcard-261381952-en.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}